332 related articles for article (PubMed ID: 10092648)
1. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.
Lee B; Sharron M; Blanpain C; Doranz BJ; Vakili J; Setoh P; Berg E; Liu G; Guy HR; Durell SR; Parmentier M; Chang CN; Price K; Tsang M; Doms RW
J Biol Chem; 1999 Apr; 274(14):9617-26. PubMed ID: 10092648
[TBL] [Abstract][Full Text] [Related]
2. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
3. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.
Siciliano SJ; Kuhmann SE; Weng Y; Madani N; Springer MS; Lineberger JE; Danzeisen R; Miller MD; Kavanaugh MP; DeMartino JA; Kabat D
J Biol Chem; 1999 Jan; 274(4):1905-13. PubMed ID: 9890944
[TBL] [Abstract][Full Text] [Related]
4. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.
Zhang J; Rao E; Dioszegi M; Kondru R; DeRosier A; Chan E; Schwoerer S; Cammack N; Brandt M; Sankuratri S; Ji C
Antimicrob Agents Chemother; 2007 Apr; 51(4):1386-97. PubMed ID: 17242138
[TBL] [Abstract][Full Text] [Related]
5. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein.
Blanpain C; Doranz BJ; Vakili J; Rucker J; Govaerts C; Baik SS; Lorthioir O; Migeotte I; Libert F; Baleux F; Vassart G; Doms RW; Parmentier M
J Biol Chem; 1999 Dec; 274(49):34719-27. PubMed ID: 10574939
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
Olson WC; Rabut GE; Nagashima KA; Tran DN; Anselma DJ; Monard SP; Segal JP; Thompson DA; Kajumo F; Guo Y; Moore JP; Maddon PJ; Dragic T
J Virol; 1999 May; 73(5):4145-55. PubMed ID: 10196311
[TBL] [Abstract][Full Text] [Related]
7. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.
Wu L; LaRosa G; Kassam N; Gordon CJ; Heath H; Ruffing N; Chen H; Humblias J; Samson M; Parmentier M; Moore JP; Mackay CR
J Exp Med; 1997 Oct; 186(8):1373-81. PubMed ID: 9334377
[TBL] [Abstract][Full Text] [Related]
8. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
[TBL] [Abstract][Full Text] [Related]
9. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
10. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
[TBL] [Abstract][Full Text] [Related]
11. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
Khurana S; Kennedy M; King LR; Golding H
J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.
Maeda K; Das D; Yin PD; Tsuchiya K; Ogata-Aoki H; Nakata H; Norman RB; Hackney LA; Takaoka Y; Mitsuya H
J Mol Biol; 2008 Sep; 381(4):956-74. PubMed ID: 18590744
[TBL] [Abstract][Full Text] [Related]
13. Peptide mimotopes selected with HIV-1-blocking monoclonal antibodies against CCR5 represent motifs specific for HIV-1 entry.
Königs C; Pustowka A; Irving J; Kessel C; Klich K; Wegner V; Rowley MJ; Mackay IR; Kreuz W; Griesinger C; Dietrich U
Immunol Cell Biol; 2007 Oct; 85(7):511-7. PubMed ID: 17607321
[TBL] [Abstract][Full Text] [Related]
14. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.
Aarons EJ; Beddows S; Willingham T; Wu L; Koup RA
Virology; 2001 Sep; 287(2):382-90. PubMed ID: 11531415
[TBL] [Abstract][Full Text] [Related]
15. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.
Dogo-Isonagie C; Lam S; Gustchina E; Acharya P; Yang Y; Shahzad-ul-Hussan S; Clore GM; Kwong PD; Bewley CA
J Biol Chem; 2012 Apr; 287(18):15076-86. PubMed ID: 22403408
[TBL] [Abstract][Full Text] [Related]
16. Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity.
Blanpain C; Lee B; Vakili J; Doranz BJ; Govaerts C; Migeotte I; Sharron M; Dupriez V; Vassart G; Doms RW; Parmentier M
J Biol Chem; 1999 Jul; 274(27):18902-8. PubMed ID: 10383387
[TBL] [Abstract][Full Text] [Related]
17. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
[TBL] [Abstract][Full Text] [Related]
18. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
19. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
Hoffman TL; LaBranche CC; Zhang W; Canziani G; Robinson J; Chaiken I; Hoxie JA; Doms RW
Proc Natl Acad Sci U S A; 1999 May; 96(11):6359-64. PubMed ID: 10339592
[TBL] [Abstract][Full Text] [Related]
20. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.
Doranz BJ; Lu ZH; Rucker J; Zhang TY; Sharron M; Cen YH; Wang ZX; Guo HH; Du JG; Accavitti MA; Doms RW; Peiper SC
J Virol; 1997 Sep; 71(9):6305-14. PubMed ID: 9261347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
